Z ika virus, a mosquito-borne flavivirus, is an emerging virus that has challenged the US public health system. Following its emergence in the Western Hemisphere in 2015, there was increased concern regarding travel-related Zika cases diagnosed in nonepidemic countries. [1] [2] [3] During the height of the epidemic, the majority of US travelers who sought consultations before traveling to Zika-affected areas in the Western Hemisphere were of reproductive age and planned to travel for vacation. 4 In 2016, travel-related cases accounted for nearly all of the probable and confirmed cases that had been reported to ArboNET, the national surveillance system for arboviral infections of the Centers for Disease Control and Prevention (CDC). 5 Most Zika virus infections are believed to be asymptomatic or mild. 6 Symptomatic patients commonly present with fever, rash, arthralgia, headache, conjunctivitis, and myalgia. 3 Less common manifestations of Zika virus infection include oral ulcers, abdominal pain, diarrhea, and neurologic syndromes such as Guillain-Barré. 7 Although the illness is typically mild, infection in pregnant women has been linked to congenital microcephaly and other complications of pregnancy. 8 Sexual transmission of Zika virus also is of public health concern, especially in nonendemic areas where non travelers may be exposed through their traveling partners. 9 The CDC recommends that healthcare providers consult with their state health departments for guidance on ordering and interpreting Zika virus tests. 10 The Council of State and Territorial Epidemiologists (CSTE) clinical criteria for the case
Key Points
• The most prevalent symptoms of Zika virus in our study population were rash, fever, headache, conjunctivitis, and myalgia.
• Travel clinics may be important in the surveillance of emerging infectious diseases because returned travelers can serve as sentinel patients for emerging infections.
• Testing protocols aimed at testing symptomatic patients may miss a majority of Zika virus infections.
definition of Zika virus-compatible illness includes having at least one of the following symptoms: maculopapular rash, fever, conjunctivitis, or arthralgia. Cases also need to have epidemiologic linkage, such as travel history to a Zika virus-affected area. 11 The typical incubation period for Zika virus exposure from the bite of an infected Aedes mosquito and symptom onset is approximately 3 to 12 days. 12 Response challenges for the US public health systemincluding initial limitations to testing resources, the size and characteristics of the at-risk patient population, and evolving recommendations for testing-impel improved characterization of patients with Zika virus infection to assist in better understanding the risks for travelers and to inform evolving evaluation guidelines. To assist in addressing this need, we analyzed a series of returned travelers presenting to an academic travel clinic with possible Zika virus infection.
Methods

Study Population
We conducted a retrospective electronic health record review of patients evaluated for Zika virus at an academic travel clinic in Atlanta, Georgia from January 1 through August 31, 2016. Inclusion criteria were patients of any age who presented to the clinic during this period for evaluation for possible Zika virus infection. Clinic physicians decided whether there was a clinical concern for Zika virus infection. We included patients with symptoms of Zika virus infection, asymptomatic patients with possible exposure to Zika virus, and patients who were referred for Zika virus testing.
Patient charts were abstracted using a case report form that captured the following patient information: age, sex, pregnancy status, travel destinations, reason for travel, travel accommodations, 
Clinical criteria
Must have ≥1 of the below:
• Acute onset of fever (measured or reported)
• Maculopapular rash use of mosquito bite prevention methods, symptoms, vaccination history (eg, yellow fever vaccine), reported history of any arboviral infection, duration from first possible exposure to symptom onset, duration from symptom onset to presentation to healthcare providers and testing, history of unprotected sex following exposure, Zika virus testing performed, and final test results. Mosquito bite prevention included any of the following methods: using insect repellant or permethrin-treated clothing, wearing long-sleeved shirts and long trousers, use of mosquito bed nets, and sleeping in screened and or air-conditioned rooms. Epidemiologic linkage was defined as travel to an area with active Zika virus transmission as reported by the CDC 13 or a history of engaging in unprotected sexual intercourse (vaginal, oral, or anal) with an exposed partner (symptomatic or asymptomatic). Typical Zika symptoms were considered those most commonly reported following infection: fever, rash, arthralgia, and conjunctivitis. Fever was based on self-reported fever and objective fever measured at the clinic. Other, less common symptoms reported in previous Zika virus outbreaks, such as cough, sore throat, oral ulcers, abdominal pain, vomiting, diarrhea, fatigue, chills, and headache were included in our case report form. 1 The Georgia Department of Public Health (GDPH) provides advice on testing criteria. The GDPH required the presence of at least two typical Zika symptoms and epidemiologic linkage to approve testing of suspected cases.
14 In addition, pregnant women (symptomatic or asymptomatic) with possible exposure to Zika virus via travel or sexual contact were tested. 14 Testing was primarily performed at either the Emory Medical Laboratories or the Georgia Public Health Laboratory (with confirmation of positive immunoglobulin M testing by a plaque reduction neutralization test done at the CDC in Fort Collins, CO).
Statistical Analysis
Case patients were classified as "confirmed" and "probable" according to CSTE clinical criteria (Table 1) . 11 Descriptive and statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC). The χ 2 and Fisher exact tests were used to assess differences between cases and noncases and tested and not-tested patients. Noncases were defined as individuals tested for Zika virus who tested negative. The tested category included both cases and noncases. We assessed statistical significance at the α = 0.05 level. The institutional review board at Emory University reviewed and approved this study.
Results
Forty-seven patients met the inclusion criteria for this case series (Fig) . One patient was excluded because electronic health record data were not available. Of the 46 patients included in our descriptive analysis, 30 (65.2%) met GDPH testing criteria. Of these, 8 (17.4%) met CSTE criteria for confirmed or probable Zika virus disease (7 confirmed, 1 probable).
None of the 5 pregnant patients tested for Zika virus were positive. Among the 16 patients who were not tested for Zika virus, 15 had epidemiologic linkages and exhibited possible Zika virus-related symptoms, but otherwise did not meet testing criteria. One additional pregnant patient with no exposure risk had possible Zika virus symptoms was not tested. Among those who were tested, the median age for cases was 34 (interquartile range, [IQR] 8.5) and 33.5 years (IQR 7.0) for noncases ( Table 2 ). Among cases, the median time from first possible exposure to symptom onset was 9 days (IQR 8.5); among symptomatic noncases, 7.5 days (IQR 8.0); and among symptomatic patients who were not tested, 6.5 days (IQR 12.0). The duration from symptom onset to seeking medical evaluation was similar for cases (7 days, IQR 11.5), noncases (6.5 days, IQR 9.0), and those not tested (6 days, IQR 6.0). Most Zika virus cases were male (62.5%) and most noncases were female (77.3%). All of the cases lived in Georgia. One patient with suspected sexual transmission tested negative for the virus. Most of those not tested had traveled to a Zika virus-affected area. Most patients traveled for tourism; all confirmed or probable cases stayed between 1 to 4 weeks, whereas most of those who tested negative stayed for <2 weeks. Most patients denied practicing any measures for mosquito bite avoidance (87.5%; Table 2 ).
Among patients tested for Zika virus, the three most frequent symptoms reported were headache (92.9%), rash (82.1%), and fever (71.4%; Table 3 ). The presence of rash differed significantly between those who were tested and not tested. All 8 cases (100%) reported rash, whereas only 15 (75.0 %) noncases reported rash. Of those not tested, none reported rash. Among the typical Zika virus symptoms, arthralgia was the least commonly reported symptom, present in only 12.5% of cases, 4.6% of noncases, and 6.3% of those not tested. Other symptoms that were more commonly present in cases were conjunctivitis, headache, diarrhea, and fatigue. Compared with those who were not tested, tested patients more frequently reported rash, conjunctivitis, headache, myalgia, and oral ulcers. Chills or sweats were significantly more frequently reported by not tested patients compared with tested patients. Among cases, the most frequently reported symptoms were rash (100%), headache (100%), fever (87.5%), myalgia (66.7%), and conjunctivitis (62.5%). Among noncases, headache (92.9%), rash (82.1%), fever (71.4%), and myalgia (59.1%) were the most frequently reported symptoms. The most common symptoms among those not tested were fever (87.5%), cough or sore throat (68.8%), headache (62.5%), myalgia (56.3%), and chills or sweats (56.3%). The median maximum temperature reported was highest among those not tested (101.8°F, IQR 3.0; 
Discussion
Here, we present a case series from a US academic-affiliated travel clinic. This article reports on our experience of evaluating patients with possible Zika virus infection during the height of the Zika virus epidemic in the Western Hemisphere in 2016. The Zika virus has presented unique clinical and public health challenges given its rapid emergence, potential to cause major congenital birth defects, and multiple modes of transmission. The most prevalent symptoms in our study population were rash, fever, headache, conjunctivitis, and myalgia, a pattern similar to earlier descriptions of Zika virus symptoms. 6 Arthralgia was less common in our study population compared with studies of travel-associated Zika virus infection in US 15 and European travelers, however. 16 As of December 2017, the total number of confirmed travel-related Zika virus cases in Georgia was 120. 17 Although the number of confirmed Zika cases in this series is low, we suspect the number of evaluations performed in our clinic was relatively high for a single site because the care of sick returned travelers in the US is typically spread out among different frontline healthcare settings. Providers in our specialty travel clinic had a heightened level of suspicion for evaluating potential Zika virus cases and were familiar with Zika virus testing criteria and procedures. Providers had a heightened level of suspicion for evaluating potential Zika virus cases, were aware of existing clinical criteria for Zika virus infection and the evolving Zika virus public health response, and were familiar with existing surveillance systems such as GeoSentinel, a global surveillance network of travel-related illnesses consisting of 63 travel and tropical medicine clinics. 2 These factors may have allowed them to more accurately document details of individual patient travel history, exposures, and the presence and timing of symptoms. As such, the rate of case ascertainment at our clinic may have been higher than in other settings. Returned travelers can serve as sentinel patients for emerging infections. Clinics such as ours have played an important role in the surveillance of emerging infectious diseases and have identified less common symptoms that may manifest in this population. 18 An additional strength is our adherence to existing criteria and guidance that makes our analysis an accurate assessment of our performance that may be generalizable to clinics in a similar practice environment.
Because of limited Zika virus testing capacity in the US during this period, the state health department implemented testing criteria that affected our ability to test asymptomatic or minimally symptomatic nonpregnant patients. Up to 80% of Zika virus patients may be asymptomatic. 6 Probable cases had not been retested to confirm their status, presenting a potential misclassification bias. Nevertheless, we do not believe misclassification was an issue with our "cases" categorization because both confirmed and probable patients were combined into one category. It is possible that some of the patients who were not tested in this series had Zika virus infection. Furthermore, CDC testing guidelines during this period (and currently) similarly do not recommend testing of asymptomatic, nonpregnant individuals. 19 As per CDC guidelines, all nonpregnant patients of child-bearing age with Zika virus exposure risk presenting to our clinic are advised to take precautions against conception (for 6 months after the last possible exposure for men and for 2 months for women) or transmission to pregnant partners regardless of Zika virus testing status. 20 It also should be noted that the World Health Organization recommends delaying conception for 6 months for men and women after possible exposure. 21 To prevent local transmission, patients in this case series who were symptomatic and tested also were encouraged to adhere to mosquito prevention methods for at least 3 weeks after illness onset.
Zika virus testing is now widely available through commercial laboratories in the US without the need for health department approval. Further description of Zika virus disease in returned travelers and test development will inform guidelines for Zika virus evaluation and management in this population. Strategies to test asymptomatic individuals are needed to improve Zika virus surveillance. Furthermore, clinical validation of Zika virus testing in asymptomatic populations would be helpful in counseling individuals who are unable or reluctant to delay conception for the recommended wait periods, and individuals with confirmed infection may be more likely to adhere to transmission prevention advice. Until effective Zika virus control is achieved in affected areas or a safe and effective Zika virus vaccine is available, general prevention measures continue to be critical during pretravel consultations, such as mosquito avoidance measures and advising pregnant women to avoid travel to affected areas. 22 
Conclusions
We found that among 30 patients meeting clinical testing criteria, 8 tested positive for Zika virus. Given that a high percentage of asymptomatic patients are expected, testing protocols aimed at symptomatic cases, including criteria for suspected cases, presumably miss a significant proportion, if not a majority, of Zika virus infections. This limits Zika virus surveillance in the US. Furthermore, because asymptomatic Zika virus-infected individuals have been documented to transmit the disease sexually, 8 limited testing protocols presumably miss cases that may contribute to local transmission. Maximizing case-capture for Zika virus, along with other emerging infections, could help further public health and research for future outbreaks. Specialized travel clinics, such as this one, could be ideal locations for this type of research.
